Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction-associated steatotic liver disease
{{output}}
Background and aim: Sarcopenia is increasingly recognized as a clinically relevant comorbidity in metabolic dysfunction-associated steatotic liver disease (MASLD), yet its epidemiology and prognostic implications in non-cirrhotic... ...
